{"id":11590,"date":"2021-01-14T15:22:21","date_gmt":"2021-01-14T09:52:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11590"},"modified":"2021-07-24T12:58:14","modified_gmt":"2021-07-24T07:28:14","slug":"recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","title":{"rendered":"Gilead and Vir collaborate; Tessera scores $230M; Teladoc &#038; Dexcom bring CGM Tech; Verve unveils lead candidate"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a4439ed96653\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a4439ed96653\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\/#Gilead_and_Vir_Biotechnology_Establish_Clinical_Collaboration\" >Gilead and Vir Biotechnology Establish Clinical Collaboration&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\/#Tessera_Therapeutics_scores_USD_230_Million_to_cure_disease\" >Tessera Therapeutics scores USD 230 Million to cure disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\/#Teladoc_Health_Dexcom_offers_CGM-powered_insights_to_Type_2_Diabetes_patients\" >Teladoc Health, Dexcom offers CGM-powered insights to Type 2 Diabetes patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\/#Verve_Therapeutics_unveils_its_lead_program_for_treating_genetically_high_cholesterol\" >Verve Therapeutics unveils its lead program for treating genetically high cholesterol&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gilead_and_Vir_Biotechnology_Establish_Clinical_Collaboration\"><\/span><strong>Gilead and Vir Biotechnology Establish Clinical Collaboration&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-hepatitis-b-virus-market\">chronic hepatitis B virus (HBV)<\/a><\/strong>.<\/p>\n\n\n\n<p>The companies schedule to initiate a Phase 2 trial assessing combination therapy for both treatment-experienced and treatment-na\u00efve people living with HBV. The multi-arm trial will gauge various combinations of selgantolimod, Gilead&#8217;s investigational TLR-8 agonist; VIR-2218, Vir&#8217;s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist.&nbsp;<\/p>\n\n\n\n<p>People in the trial with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-b-virus-hbv-infection-pipeline-insight\">HBV treatment<\/a><\/strong> experience may also receive Gilead&#8217;s Vemlidy (tenofovir alafenamide fumarate, TAF). The study&#8217;s primary result will be the proportion of patients attaining a functional treatment, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.<\/p>\n\n\n\n<p>Both companies retain full rights to their product candidates and discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tessera_Therapeutics_scores_USD_230_Million_to_cure_disease\"><\/span><strong>Tessera Therapeutics scores USD 230 Million to cure disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Technologists are getting better at coding biology, and venture firms are flooding a new generation of startups with cash to commercialize their technology bringing in the next wave of genetic innovation.<\/p>\n\n\n\n<p>Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with USD 230 million in new financing to build up its platform for better biological programming.<\/p>\n\n\n\n<p>The round was led by Alaska Permanent Fund Corp., Altitude Life Science Ventures, and the second SoftBank Vision Fund, with participation from the Qatari Investment Authority and other undisclosed investors.<\/p>\n\n\n\n<p>Last year, the company disclosed its gene-writing service, which combined various gene editing, manufacturing, and synthesizing technologies to provide more tailored therapeutic instructions to genetic code.<\/p>\n\n\n\n<p>By providing more instructions to genetic material, the company aims to increase the precision of therapies while expanding the number of potential pathogens or mutations they can target, the company said in a statement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teladoc_Health_Dexcom_offers_CGM-powered_insights_to_Type_2_Diabetes_patients\"><\/span><strong>Teladoc Health, Dexcom offers CGM-powered insights to Type 2 Diabetes patients<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Teladoc Health, Inc., the first and only complete virtual care system, and DexCom, Inc., the leader in real-time continuous <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\">glucose monitoring<\/a><\/strong> (CGM), announced that joint Livongo for Diabetes and Dexcom members will now get CGM-powered insights, a new set of features and reports, which help members more easily visualize their health information and comprehend how lifestyle decisions affect their blood glucose levels.&nbsp;<\/p>\n\n\n\n<p>Combining Dexcom CGM data with more signals from Teladoc Health, comprising activity data and food intake, CGM-powered insights proffer members a complete health profile and recommendations that back ongoing diabetes management.&nbsp;<\/p>\n\n\n\n<p>In January 2020, Livongo merged with Teladoc Health in October, and Dexcom announced the first phase of their strategic relationship, a data-sharing deal for Livongo for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\">Diabetes <\/a><\/strong>members using Dexcom CGM technology.&nbsp;<\/p>\n\n\n\n<p>Teladoc Health and Dexcom will launch a pilot exhibiting the impact of CGM-powered insights for people affected with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-pipeline-insight\">Type 2 diabetes<\/a><\/strong>. Eligible members will get an integrated product experience, comprising the Livongo for Diabetes program, Dexcom CGM technology, and CGM-powered insights at no cost. Through the pilot, members will receive a new experience that examines their health data and trends with the mutual goal of improving health outcomes. Teladoc Health and Dexcom plan to launch the pilot more broadly throughout 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Verve_Therapeutics_unveils_its_lead_program_for_treating_genetically_high_cholesterol\"><\/span><strong>Verve Therapeutics unveils its lead program for treating genetically high cholesterol&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Verve Therapeutics has an aim to bring one-and-done gene editing treatments to <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-heart-failure-ahf-market\">heart disease<\/a><\/strong>. Now, the company is moving toward the clinic to treat a genetic form of high <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cholesterol-absorption-inhibitor-pipeline-insight\">cholesterol<\/a><\/strong>.<\/p>\n\n\n\n<p>The treatment, VERVE-101, is a base editor; that is, it does not cut DNA as CRISPR gene editing systems do. Instead, it changes one base, or letter, in the genome to a different one without affecting the letters around it. Its first target is an inherited form of high cholesterol called heterozygous <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market\">familial hypercholesterolemia<\/a><\/strong>, or HeFH.<\/p>\n\n\n\n<p>People affected by HeFH have a gene mutation in the liver that causes very high cholesterol levels and leads to heart attacks or strokes relatively early in life. VERVE-101 is designed to cut those cholesterol levels by hindering the PCSK9 gene.<\/p>\n\n\n\n<p>The treatment is a lipid nanoparticle involving a guide RNA to search the target letter on the PCSK9 and an mRNA that changes an A base in the gene to a G, hence inactivating the gene and lowering cholesterol.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead and Vir Biotechnology Establish Clinical Collaboration&nbsp; Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). The companies schedule to initiate a Phase 2 trial assessing combination therapy for both [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":11593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18750,18749,794,420,639,18748,18747,18237],"industry":[17225],"therapeutic_areas":[17242,17240,17227],"class_list":["post-11590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cgm-tech","tag-dexcom","tag-gilead","tag-news","tag-pharma-news","tag-teladoc","tag-tessera","tag-vir","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead-Vir&#039;s deal; Tessera bags $230M; Verve&#039;s VERVE-101; CGM Tech<\/title>\n<meta name=\"description\" content=\"Teladoc Health, the first and only complete virtual care system, and DexCom, the leader in real-time CGM announced that joint Livongo for..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead-Vir&#039;s deal; Tessera bags $230M; Verve&#039;s VERVE-101; CGM Tech\" \/>\n<meta property=\"og:description\" content=\"Teladoc Health, the first and only complete virtual care system, and DexCom, the leader in real-time CGM announced that joint Livongo for..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T09:52:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead-Vir's deal; Tessera bags $230M; Verve's VERVE-101; CGM Tech","description":"Teladoc Health, the first and only complete virtual care system, and DexCom, the leader in real-time CGM announced that joint Livongo for..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","og_locale":"en_US","og_type":"article","og_title":"Gilead-Vir's deal; Tessera bags $230M; Verve's VERVE-101; CGM Tech","og_description":"Teladoc Health, the first and only complete virtual care system, and DexCom, the leader in real-time CGM announced that joint Livongo for..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-01-14T09:52:21+00:00","article_modified_time":"2021-07-24T07:28:14+00:00","og_image":[{"width":750,"height":420,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve","name":"Gilead-Vir's deal; Tessera bags $230M; Verve's VERVE-101; CGM Tech","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve.jpg","datePublished":"2021-01-14T09:52:21+00:00","dateModified":"2021-07-24T07:28:14+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Teladoc Health, the first and only complete virtual care system, and DexCom, the leader in real-time CGM announced that joint Livongo for..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-vir-teladoc-tessera-dexcom-verve#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve.jpg","width":750,"height":420,"caption":"recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/01\/14151719\/recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve-300x168.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CGM Tech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dexcom<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teladoc<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tessera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vir<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CGM Tech<\/span>","<span class=\"advgb-post-tax-term\">Dexcom<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Teladoc<\/span>","<span class=\"advgb-post-tax-term\">Tessera<\/span>","<span class=\"advgb-post-tax-term\">Vir<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 14, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 14, 2021 3:22 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11590"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11593"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11590"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11590"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}